| 1. |
Tarling JA, Kumar R, Ward LJ, et al. Phaeochromocytoma and paraganglioma. J Clin Pathol, 2024, 77(8): 507-516.
|
| 2. |
中華醫學會內分泌學分會. 嗜鉻細胞瘤和副神經節瘤診斷治療專家共識(2020 版). 中華內分泌代謝雜志, 2020, 36(9): 737-750.
|
| 3. |
Sikkema T, Uyttenboogaart M, Eshghi O, et al. Intracranial artery dissection. Eur J Neurol, 2014, 21(6): 820-826.
|
| 4. |
楊新健, 劉建民, 張義森, 等. 顱內夾層動脈瘤的血管內治療中國專家共識. 中華神經外科雜志, 2018, 34(8): 757-763.
|
| 5. |
Melmed S, Polonsky KS, Reed Larsen P, et al. Williams textbook of endocrinology. 12th ed. Philadelphia, PA: Elsevier, 2011.
|
| 6. |
Karel P. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab, 2007, 92(11): 4069-4079.
|
| 7. |
Farrugia FA, Charalampopoulos A. Pheochromocytoma. Endocr Regul, 2019, 53(3): 191-212.
|
| 8. |
Naranjo J, Dodd S, Martin YN. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth, 2017, 31(4): 1427-1439.
|
| 9. |
Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2014, 99(6): 1915-1942.
|
| 10. |
袁文祺, 王衛慶. 嗜鉻細胞瘤的圍手術期處理. 中國實用內科雜志, 2010, 30(9): 846-847.
|
| 11. |
Kong H, Li N, Li XY, et al. The role of pre-operative α-blockade in patients with normotensive phaeochromocytoma or paraganglioma: a retrospective cohort study. Eur J Anaesthesiol, 2018, 35(11): 898-899.
|
| 12. |
田杰, 孔昊, 李楠, 等. 腎上腺偶發嗜鉻細胞瘤術中血流動力學不穩定的危險因素分析. 中華泌尿外科雜志, 2019, 40(4): 262-266.
|
| 13. |
Ulchaker JC, Goldfarb DA, Bravo EL, et al. Successful outcomes in pheochromocytoma surgery in the modern era. J Urol, 1999, 161(3): 764-767.
|
| 14. |
Shao Y, Chen R, Shen ZJ, et al. Preoperative alpha blockade for normotensive pheochromocytoma: is it necessary?. J Hypertens, 2011, 29(12): 2429-2432.
|
| 15. |
Lentschener C, Gaujoux S, Thillois JM, et al. Increased arterial pressure is not predictive of haemodynamic instability in patients undergoing adrenalectomy for phaeochromocytoma. Acta Anaesthesiol Scand, 2009, 53(4): 522-527.
|
| 16. |
Boutros AR, Bravo EL, Zanettin G, et al. Perioperative management of 63 patients with pheochromocytoma. Cleve Clin J Med, 1990, 57(7): 613-617.
|
| 17. |
Groeben H, Nottebaum BJ, Alesina PF, et al. Perioperative α-receptor blockade in phaeochromocytoma surgery: an observational case series. Br J Anaesth, 2017, 118(2): 182-189.
|
| 18. |
Neumann HPH, Young WF, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med, 2019, 381(6): 552-565.
|
| 19. |
Brogden RN, Heel RC, Speight TM, et al. alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use. Drugs, 1981, 21(2): 81-89.
|
| 20. |
Naruse M, Satoh F, Tanabe A, et al. Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan. Endocr J, 2018, 65(3): 359-371.
|
| 21. |
Fang F, Ding L, He Q, et al. Preoperative management of pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne), 2020, 11: 586795.
|
| 22. |
Ramachandran R, Rewari V. Current perioperative management of pheochromocytomas. Indian J Urol, 2016, 33(1): 19-25.
|
